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Background: HIV-infected individuals transitioning from
incarceration to the community are at risk for loss of viral
suppression. We compared the effects of imPACT, a multidimen-
sional intervention to promote care engagement after release,
to standard care on sustaining viral suppression after
community re-entry.
Methods: This trial randomized 405 HIV-infected inmates being
released from prisons in Texas and North Carolina with HIV-1
RNA levels,400 copies/mL to imPACT versus standard care. The
imPACT arm received motivational interviewing prerelease and
postrelease, referral to care within 5 days of release, and
a cellphone for medication text reminders. The standard care arm
received routine discharge planning and a cellphone for study staff
contact. The primary outcome was the difference between arms in
week 24 postrelease viral suppression (HIV-1 RNA ,50 copies/
mL) using intention-to-treat analysis with multiple imputation of
missing data.
Results: The proportion with 24-week HIV-1 RNA ,50 copies/
mL was 60% and 61% in the imPACT and standard care arms,
respectively [odds ratio for suppression 0.95 (95% confidence
interval: 0.59 to 1.53)]. By week 6 postrelease, 86% in the
imPACT arm versus 75% in the standard care arm attended at
least 1 nonemergency clinic visit (P = 0.02). At week 24, 62% in
both arms reported not missing any antiretroviral doses in the past
30 days (P . 0.99).
Conclusions: Higher rates of HIV suppression and medical care
engagement than expected based on previous literature were observed
among HIV-infected patients with suppressed viremia released from
prison. Randomization to a comprehensive intervention to motivate
and facilitate HIV care access after prison release did not prevent loss
of viral suppression. A better understanding of the factors influencing
prison releasees’ linkage to community care, medication adherence,
and maintenance of viral suppression is needed to inform policy and
other strategic approaches to HIV prevention and treatment.
Key Words: prison, prisoners, adherence, retention, behavioral
interventions
(J Acquir Immune Defic Syndr 2017;75:81–90)
INTRODUCTION
The efficacy of antiretroviral therapy (ART) in prevent-
ing secondary HIV transmission coupled with the recognition
that many HIV-infected persons in the United States are
undiagnosed or not in care have led to a strategy to expand
HIV testing, and strengthen the uptake and continued use of
HIV therapy for those infected.1–9 This multifaceted seek, test,
treat, and retain approach to HIV prevention is readily applied
to correctional settings, such as prisons, where the prevalence
of HIV infection is several times that of the general population,
and routine HIV screening provides opportunities for detection
and treatment during incarceration.10–13
Although HIV testing is commonplace in US prisons
and ART is freely accessible to inmates,13 retention in HIV
care after prison release has been reported to be less
successful. In an analysis of ART prescription fill records
for 2115 individuals released from state prison in Texas from
2004 to 2007, 55% with a plasma HIV RNA level below the
limits of assay detection just before release, only 30% of
releasees had filled their ART prescription by 60 days after
community re-entry.14 Postrelease HIV RNA level data were
not collected. Achievement of an undetectable plasma HIV
RNA level was the primary outcome of a substudy of 94 HIV-
infected patients with a history of opioid dependence
participating in a larger randomized trial of directly observed
administration of ART after prison release in Connecticut.15
At baseline, 54% had an undetectable viral load, and this was
largely unchanged by 24 weeks after release when 58% had
viral suppression. The highest rate of controlled viremia was
among those who were maintained on buprenorphine (82%)
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and lowest rate was observed in the control arm that did not 
receive substitution therapy (55%). There was no significant 
effect of directly observed administration of ART on viral 
suppression in this or the larger parent trial. Studies of HIV-
infected prisoners who were released and then reincarcerated 
provide additional virologic outcome data after prison release, 
and in these, viral suppression at reincarceration has been 
found to be the exception rather than the rule.16,17
Interventions to support HIV care, ART adherence, and 
viral suppression after prison release also have been explored. 
Zaller et al18 described the successful implementation of 
a comprehensive case management program linking over 
95% of incarcerated HIV-infected prison releasees to commu-
nity care and services in Rhode Island. However, a controlled 
trial of a similar intervention that enrolled 104 HIV-infected 
prisoners released in North Carolina found no significant 
difference in 24-week rates of community medical care access 
between those randomized to the intervention (92%) and to 
standard discharge planning conducted by prison staff (89%).19 
Virologic outcomes were not assessed.
Almost all the previous research that has examined HIV-
related clinical outcomes after prison release in the United 
States was conducted a decade ago, when ART tended to be 
more cumbersome and less forgiving of all but high-level 
adherence. Furthermore, individuals with suppressed and 
detectable viremia at the time of prison release were typically 
enrolled—mixing the maintenance of viral suppression with 
the achievement of viral suppression after community re-entry.
Given the limitations of the research published to date 
and the importance to successful HIV prevention of devel-
oping interventions that effectively support the continuity of 
HIV care and maintenance of ART through the transition 
from imprisonment to community re-entry, we developed 
a multidimensional intervention rooted in the seek, test, treat, 
and retain approach, called imPACT (Individuals Motivated 
to Participate in Adherence, Care and Treatment).20 Designed 
to promote engagement in HIV care after release for HIV-
infected prisoners, imPACT consisted of 3 main components: 
motivational interviewing before and after release, prerelease 
needs assessment and community medical care link coordi-
nation, and cellphone provision with texted reminders before 
each antiretroviral medication dose. By design, the focus of 
the imPACT intervention was linkage to community clinics, 
where assessments of need could be conducted and support-
ive services provided.
In a randomized controlled trial conducted in Texas and 
North Carolina—states that combined incarcerate approxi-
mately 1 in 7 of all prison inmates in the United States—the 
imPACT intervention was compared with the standard 
discharge planning for maintaining viral suppression in 




Eligible participants were HIV-infected men and 
women, age 18 years and older incarcerated within the Texas
Department of Criminal Justice (TDCJ) or North Carolina 
Department of Public Safety (NCDPS) prison, treated with 
ART with a recorded plasma HIV RNA level of ,400 copies/
mL within the past 90 days, and expected to be released to the 
community within approximately 12 weeks. In addition, 
participants were required to be English speaking and, 
to minimize risk to study staff, to have not been convicted 
of violent offenses, such as those related to sexual assault, 
serious injury, or death. All had to be willing and able to 
provide written informed consent.
Study screening and recruitment occurred at prison 
medical clinics during routine visits or in a secured room 
within the prison unit. Interested patients met in a secure but 
private area with a research associate, who, as part of the 
informed consent process, explained the study and answered 
questions regarding participation.
The institutional review boards at Texas Christian 
University and the University of North Carolina, as well as 
human subjects committees at both prison systems and the US 
Office of Human Research Programs (OHRP), approved this 
research. Recognizing that those enrolled are a vulnerable 
population, the study team undertook a number of measures 
to minimize the risk of coercion. These included developing 
a script that explained in simple terms that participation was 
voluntary and conferred no special privileges or consider-
ation. In addition, discussion of the study and the consent 
process occurred in private, without correctional staff present. 
Lastly, we developed and administered a short set of 
questions to determine whether the patient understood the 
study rationale, procedures, and voluntary nature.
Intervention and Randomization
Eligible participants were randomized 1:1 after the 
completion of baseline data collection to standard-of-care 
discharge planning versus the imPACT intervention. Ran-
domization was stratified by state. Figure 1 details events in 
both the standard-of-care and the intervention study groups.
Standard of Care
In both states, over 90% of inmates are tested at prison 
entry, and HIV care, including ART, is provided to infected 
inmates at no cost. Prison staff in both states routinely 
perform discharge planning before release, which included 
referrals to community clinics, arrangements for housing, and 
other services when available and based on their assessments 
of need.
In both states, the prison system provided a supply of 
antiretroviral medications to HIV-infected releasees at the 
time of release (per state policy: a 10-day supply in Texas and 
a 30-day supply in North Carolina).
Cellphone Distribution
Standard-of-care participants were provided with a flip-
type cellphone immediately after release to maintain partic-
ipant contact and enhance retention. In both study arms and in 
both states, cellphones were used to remind participants of 
upcoming study visits and to conduct unannounced 
pill counts.
imPACT Intervention weeks through telephone after release. Each in-person and
phone motivational interviewing session was conducted
using a stepwise guide based on motivational interviewing
interventions that we had developed previously.21,28–31 As
a part of the session, the motivational interviewing counselor
and participant together created graphic cognitive “maps” to
visually represent and connect thoughts, feelings, and
actions evoked, as well as clarify participant goals after
release. Before each in-prison motivational interviewing
session, participants were shown one of two 15 to 20-
minute videos that were produced specifically for the trial
and provided an orientation to the intervention and prepared
the participant for each upcoming motivational interviewing
session. After release, the same motivational interviewing
counselor who met with the participant in prison conducted
the 6 phone sessions.
Needs Assessment and Brief Link Coordination
Within 4 weeks before release, a study Link Coordina-
tor met with the participant 1 time to conduct an evaluation of
anticipated needs after community re-entry, using a standard-
ized set of questions.22 The Link Coordinator scheduled
a community clinic appointment for the participant and
submitted applications for state and pharmaceutical company
drug assistance programs, when needed. Link Coordinators
conducted encounters with the participant in person before
release and by telephone after release. If the initial clinic
FIGURE 1. Screening, enrollment,
and follow-up. *Includes 3 partic-
ipants who completed week 24 but
for whom plasma HIV RNA was
unable to be performed.
Details regarding the basis and development of the 
imPACT intervention have been described elsewhere.20 
Briefly, the imPACT intervention adapted and combined 
existing theoretically rooted interventions21–23 to be influ-
ential at the individual, clinic/institutional, and community 
levels in accordance with the Social Ecological Frame-
work.24,25 Conceptually, the imPACT intervention was 
designed to enhance motivation and self-efficacy to attend 
community HIV care visits and adhere to ART after release, 
while also reducing barriers to such care. The overarching 
objective of the intervention was to maintain viral suppres-
sion after prison release, and entry into community medical 
care was presumed to be the critical mediator of this 
outcome. The intervention was finalized after formative 
research conducted with prison-based and community 
service providers as well as former inmates living with 
HIV infection, as has been previously reported.26,27 The 
main elements of the tested intervention included 
the following:
Motivational Interviewing Augmented by Cognitive 
Mapping
A trained motivational interviewing counselor con-
ducted 2 individual face-to-face sessions in prison (lasting 
approximately 1 hour each) followed by 6 additional 
sessions scheduled approximately every 2 weeks over 14
appointment was not kept by the participant, the Link 
Coordinator was instructed to make 1 additional clinic 
appointment on behalf of the participant. All interactions 
between the Link Coordinator and the participant ceased 
either once the arranged clinic appointment was attended or 
after the second missed appointment.
Cellphone Distribution and Text Message Antiretroviral 
Medication Reminders
Each participant randomized to the imPACT interven-
tion was given a flip-type cellphone by a research assistant as 
soon as possible (typically within 3 days) after release. These 
research assistants programed each study cellphone with up to 
10 telephone numbers for the participant, including those of 
the Link Coordinator, Motivational Interview (MI) Coun-
selor, research assistant, community case manager (if appli-
cable), and community clinic and others selected by the 
participant. In addition, the phones were used to send 
medication reminder text messages to the participant 15 mi-
nutes before each scheduled antiretroviral dose for the first 12 
weeks after release to support adherence. Text message 
timing and wording were customized to the participant’s 
antiretroviral regimen and preference at the time of release 
(eg, take your vitamins) and were followed in 15 minutes by 
a query text asking if the medication was taken (eg, Did you 
take your vitamins?) and instructions to press 1 for “yes” and 
2 for “no.” When the response was yes, a text thanking the 
participant for responding was sent. When the response was 
no or in cases of no response, the query text was resent once 
again 30 minutes later.
Assessments and Outcomes
Participants completed a baseline study visit in prison 
and then a prerelease visit approximately 2–4 weeks before 
anticipated release. Immediately after release, research assis-
tants met briefly with all participants to deliver the study 
cellphone, study staff business cards, a pill counting tray and 
spatula, and a locking backpack with toiletries and condoms. 
Postrelease study visits were scheduled at weeks 2, 6, 14, and 
24 and were conducted at public locations selected by the 
research assistant and the participant.
HIV Viral Load
The proportion of participants in each study arm with 
a plasma HIV-1 RNA level below 50 copies/mL at 24 
weeks after release was the primary outcome of the trial. 
Blood was collected at each of the postrelease study visits 
(weeks 2, 6, 14, and 24) for plasma HIV-1 RNA poly-
merase chain reaction levels. All blood specimens were 
delivered to Laboratory Corporation of America (Labcorp) 
and were analyzed in batches. Baseline HIV RNA levels 
and CD4+ cell counts were those last obtained as part of 
clinical care during incarceration within the 60 days before 
study entry.
Clinical Care Engagement
At each study visit, in surveys administered through 
audio computer-assisted self-interviews, participants were
asked to list all the outpatient encounters they had since the 
last study visit and to characterize whether the encounter was 
for HIV care or not (eg, substance abuse treatment). A 
participant who indicated that they attended at least 1 
nonemergency outpatient medical clinic visit within 6 weeks 
of release was considered engaged in clinical care.
Other Variables
At baseline, demographic information was collected 
and psychological functioning and mental health status 
assessed using the TCU PSY Form and TCU HLTH Form, 
both previously demonstrated to have high reliable and 
validity in this population.32,33 Medication adherence was 
self-reported using a 30-day visual analog scale.34 Substance 
use history was obtained at the baseline visit using the 
Alcohol Use Disorders Identification Test (AUDIT).35 In TX, 
the TCU Drug Screen II Form, previously found to be highly 
accurate for detecting substance use disorders among prison 
inmates,32,36,37 was administered; in NC, inmates receive the 
Substance Abuse Subtle Screening Inventory (SASSI)38 
routinely on admission. Medical and incarceration histories 
were collected through record review. After release, access to 
care, service utilization, health insurance coverage, and 
incarceration status were assessed at each visit.
Statistical Methods
The primary endpoint, the proportion of participants 
with 24-week HIV-1 RNA ,50 copies/mL, was compared 
across the 2 randomized arms using the intention-to-treat 
(ITT) principle. In addition, we report the odds ratio (OR) and 
95% confidence interval (CI) estimated from a logistic 
regression model fit by maximum likelihood; an unadjusted 
model was fit as well as a model adjusted for site and baseline 
HIV-1 RNA level. The primary analysis used multiple 
imputation because we anticipated nontrivial missing 
data.39,40 We used a multivariate normal model, in the SAS 
procedure MI to impute missing HIV-1 RNA levels 50 times 
and combined imputations using the Rubin rule.41 Variables 
included in the imputation model were age, sex, race/
ethnicity, CD4+ cell count, length of incarceration, marriage 
status, education, substance use, measures of health and well-
being, and psychological distress—all measured at baseline. 
We also performed a complete case analysis which only 
included participants with an available 24-week HIV-1 
RNA level.
We performed bounded analyses using simple impu-
tation of missing outcome data where we first assumed that 
all 24-week missing HIV-1 RNA levels among the 
intervention arm were less than 50 copies/mL  and all  
missing values among the standard-of-care arm were 
greater than 50 copies/mL (best case scenario). Secondly, 
we assumed that all missing outcome data among the 
intervention arm were greater than 50 copies/mL, and all 
missing values among the standard-of-care arm were less 
than 50 copies/mL (worst case scenario). For the primary 
ITT analyses, we also assessed alternate HIV-1 RNA 
endpoints including the comparison of continuous plasma 
HIV-1 RNA levels and viremia copy-years from
Baseline Characteristics
The participants were mostly black men, and most had
been incarcerated less than 1 year (Table 1). The median
baseline CD4+ cell count was 505/mm3 (interquartile
range [IQR], 328–724). The median age was 44 years
FIGURE 2. HIV RNA during follow-up between groups, ac-
cording to (A) complete case and (B) multiple imputation for
missing data.
randomization through week 36 across the 2 randomized 
arms. Viremia copy-years is the number of copies of HIV-1 
RNA per mL over time, and specifics of how it is calculated 
have been previously described.42 Briefly, the HIV-1 RNA 
burden for each time interval between 2 consecutive HIV-1 
RNA values was calculated by multiplying the mean of the 
2 HIV-1 RNA values by the time interval. The copy · year/
mL for each time interval of a participant’s HIV-1 RNA  
curve was then summed to calculate viremia copy-years.
Engagement in medical care at week 6 after release 
and across study follow-up was also compared. We used 
time-to-event methods including Kaplan–Meier survival 
curves to describe the time to the first nonemergency clinical 
visit after release. Incidence rates of attending a clinic visit 
were calculated as the number of visits attended divided by 
person-time under observation, and incidence rate differ-
ences were calculated with measures of precision based on 
a Poisson distribution.
The target sample size of the study (n  = 514)  was  
based on the primary endpoint comparison of the pro-
portion of participants with 24-week HIV-1 RNA ,50 
copies/mL. This estimate assumed 80% statistical power, 
a 2-sided alpha of 0.01, a 15% absolute difference in the 
primary outcome between the intervention and control 
arms, 20% loss to follow-up, and was based on performing 
a complete case analysis. Our  final sample size (n = 405) 
was lower than projected because of funding restrictions 
and corresponded to approximately 70% statistical power 
relying on the same assumptions. Because we imputed 
missing outcome data, our projected statistical power 
would have been somewhat greater than estimated. Statis-
tical analyses were performed using SAS version 9.4 (The 
SAS Institute Inc., Cary, NC). All P-values were 2-sided, 





Enrollment began in March 2012, and the last study 
visit was completed in February 2015. A total of 405 
participants were enrolled and randomized in TX (n = 242) 
and NC (n = 163) (Fig. 2). Of these participants, 24 (6%) 
were withdrawn, as they became ineligible, most because of 
an extension of prison sentence or by becoming recognized 
as a threat to study staff safety that was too high for study 
participation. Of the 2 others excluded, one planned to move 
to a location outside the study boundaries, and the other was 
detained by immigration. Of the remaining participants, 195 
were randomized to receive the intervention and 186 
participants to receive standard of care. Overall, 125 
(33%) participants did not complete 24 weeks of postrelease 
study participation, 67 (34%) in the intervention arm and 58 
(31%) in the standard-of-care arm. The primary reasons for 
study noncompletion were comparable across randomized 
arms and included reincarceration and loss to follow-up 
(Fig. 2).
Suppression of Plasma HIV-1 RNA
The ITT estimated proportion with 24-week HIV-1
RNA ,50 copies/mL was 60% and 61% in the intervention
and standard care arms, respectively. The corresponding
estimated OR for HIV-1 RNA suppression at week 24
postrelease comparing intervention to standard of care was
0.95 (95% CI: 0.59 to 1.53) (Table 2). This ITT estimate was
unaltered after adjustment for site and baseline HIV-1 RNA
level. Overall, 256 (67%) participants completed study
follow-up through week 24 postrelease, and 253 had available
week 24 HIV-1 RNA levels (2 HIV-1 RNA measures were
unavailable and 1 had insufficient volume for quantitation).
The estimated intervention effect based on the complete case
analysis was 0.94 (95% CI: 0.56 to 1.56).
Our findings were also robust to including the 24
participants who were randomized but withdrawn, OR = 0.97
(95% CI: 0.60 to 1.55). Results were also similar in analyses
using HIV-1 RNA ,400 copies/mL at week 24 as the
outcome, in both the ITT multiply imputed and complete case
analyses, with OR = 1.06 (95% CI: 0.63 to 1.79) and OR =
1.08 (95% CI: 0.60 to 1.93), respectively. Sensitivity analyses
exploring the best case scenario by replacing missing out-
come data with HIV-1 RNA ,50 and $50 copies/mL among
the intervention and standard-of-care arms, respectively,
produced an estimated intervention effect of OR = 4.04
(2.61–6.24). In the worst case scenario, where missing
outcome data were replaced with HIV-1 RNA $50 and
,50 copies/mL among the intervention and standard-of-care
arms, respectively, an estimated intervention effect of OR =
0.22 (95% CI: 0.14 to 0.35) was produced.
At baseline and throughout study follow-up until 24
weeks after release, the standard-of-care arm was less likely to
have HIV-1 RNA ,50 copies/mL than the intervention arm,
although these differences were not statistically significant with
the exception of week 6 postrelease (Fig. 3). These results
persisted after adjustment for differences at baseline in the
proportion with a plasma HIV-1 RNA level ,50 copies/mL.
Viremia copy-years was also comparable for the intervention
and standard care arms with a median of 3.6 log10 copy · year/
mL (IQR, 3.4–4.8) and 3.7 (IQR, 3.4–5.7), in the intervention
and standard-of-care arms, respectively (P = 0.36).











Median 44 43 44
IQR 35–49 34–50 35–49
Male sex, n (%) 147 (79) 150 (77) 297 (78)
Race, n (%)
White 46 (24) 39 (21) 85 (22)
Black 121 (62) 128 (69) 249 (65)
Other 28 (14) 19 (10) 47 (12)
Hispanic, n (%) 7 (6) 12 (9) 27 (7)
CD4 cell count/mm3*
Median 490 511 505
IQR 339–709 300–734 328–724
HIV RNA copies/mL, n (%)†
,50 75 (38) 60 (32) 135 (35)
,75 106 (54) 99 (53) 205 (54)
,200 9 (5) 15 (8) 24 (6)
,400 4 (2) 12 (6) 16 (4)
$400 1 (,1) 0 1 (,1)
History of substance use, n (%)* 127 (68) 116 (66) 243 (67)
Incarceration length, yr*
Median 0.77 0.84 0.81
IQR 0.49–1.82 0.50–1.92 0.49–1.88
Health and well-being, n (%)
Excellent 58 (30) 53 (28) 111 (29)
Very good/good 101 (52) 93 (50) 194 (51)
Fair/poor 36 (18) 40 (22) 76 (20)
Psychological distress, n (%)
,High 129 (66) 133 (72) 262 (69)
High 22 (11) 24 (13) 46 (12)
Very high 44 (23) 29 (16) 73 (19)
Education, n (%)
Some high school 76 (39) 80 (43) 156 (41)
High school/General Education
Development (GED)
73 (37) 61 (33) 134 (35)
Some college/trade school 46 (24) 45 (24) 91 (24)
Marital status, n (%)
Married 33 (17) 24 (13) 57 (15)
Formerly married 47 (24) 35 (19) 82 (22)
Never married 115 (59) 127 (68) 242 (64)
Functional health literacy, n (%)*
Inadequate 7 (3) 5 (4) 12 (4)
Adequate 13 (9) 8 (6) 21 (8)
Functional 121 (86) 122 (90) 243 (88)
*Missing values for CD4 cell count (n = 1), substance use (n = 17), incarceration
length (n = 6), and health literacy (n = 105).
†Categories for HIV RNA are not mutually exclusive, as they represent the assay
lower limit of detection; however, each participant is counted only once.
TABLE 2. HIV RNA at 24 Weeks After Release Between Groups,
According to Multiple Imputation for Missing Data and
Adjustment for Site and Baseline HIV RNA
Analysis Cohort*
24-Week HIV RNA ,50
Copies/mL Percent (No. of
Participants)
OR (95% CI)Intervention Standard Care
ITT (multiply imputed) 60 (195) 61 (186)
Unadjusted 0.95 (0.59 to 1.53)
Adjusted 0.96 (0.60 to 1.55)
Complete case 62 (128) 63 (125)
Unadjusted 0.94 (0.56 to 1.56)
Adjusted 0.92 (0.55 to 1.54)
*Adjusted estimates are adjusted for site and baseline HIV RNA.
(IQR, 35–49), 64% had never married, 59% completed high 
school (or equivalent), 31% reported high or very high 
psychological distress, and two-thirds reported a history of 
substance use. Baseline characteristics were not statistically 
significantly different between the 2 randomized arms.
with and without insurance, respectively, having HIV-1 RNA
,50 copies/mL (P = 0.18).
Self-reported adherence at week 24 postrelease was also
comparable across study arms, with 62% reporting not
missing any ART doses in the past 30 days in both the
intervention and standard-of-care arms (P . 0.99). However,
virologically suppressed participants were more likely to
report perfect adherence in the past 30 days in comparison
with those not virologically suppressed (70% versus 48%,
respectively, P ,0.01).
Completion of Intervention Components
All but 5 participants in the intervention arm completed
the 2 in-prison motivational interviewing sessions. Those who
did not complete motivational interviewing were released
sooner than expected, became ineligible, or were unavailable
because of prison lock down. All but 2 of those in the
intervention arm completed the face-to-face prerelease meet-
ing with the study Link Coordinator. Cellphones were
provided to 187 (95.8%) of the intervention participants
[and 180 (96.8%) of the standard-of-care participants]; those
immediately lost to follow-up after release or who were
residing in a community facility that disallowed cellphones
were not provided a cellphone.
After release, fidelity to the 6 phone-based motivational
interviewing sessions ranged from 83.6% for the first session
to 56.4% for the last session. The median number of
postrelease motivational interviewing sessions was 3.9.
DISCUSSION
In this first randomized trial of an intervention to
maintain control of viremia among HIV-infected men and
FIGURE 3. Timeline of events for intervention and control study arms.
Engagement in Clinical Care After Release
By week 6 after release, 323 participants completed at 
least 1 study visit, and among these participants, 138 (86%) in 
the intervention arm versus 122 (75%) in the standard-of-care 
arm attended at least 1 nonemergency medical clinic out-
patient visit (P = 0.02). The 260 patients with at least 1 
medical clinic visit reported 438 nonemergency clinical visits, 
with 71% at an HIV clinic. Restricting to HIV clinic visits, 
108 (67%) and 107 (66%) in the intervention versus standard 
care arms, respectively, attended at least 1 HIV clinic visit by 
week 6 postrelease (P = 0.91).
During the 24-week study follow-up, the average 
number of nonemergency medical clinic visits each 
participant reported while under study observation was 
2.9 and 2.8 for the intervention versus the standard-of-care 
participants, respectively (P = 0.53). Results were com-
parable when considering visits designated by the partic-
ipant as occurring in HIV clinics with 2.2 versus 2.1 visits 
occurring per 24 weeks in intervention and standard-of-
care groups, respectively (P = 0.31). The median time to 
first medical clinic appointment after release was slightly 
but statistically significantly shorter in the intervention 
arm compared with the standard-of-care arm (10 days 
versus 13 days, P = 0.03).
At 24 weeks after release, a similar proportion of 
participants in the intervention and control arms reported 
having any health insurance coverage (58% and 63%, 
respectively, P = 0.42). Participants reported having Medicaid 
(42%), Medicare (23%), Private insurance (11%), Military 
health care (3%), and another type of government-sponsored 
health plan (42%), with most participants reporting only 1 
type of health insurance (79%). There was no difference in 
the primary outcome of being virologically suppressed at 24 
weeks by insurance coverage, with 59% and 67% of those
women being released from prison, we found higher levels of 
viral suppression and care engagement than expected based 
on findings of previous studies of prison and jail releasees.14–
17,19,43 Approximately 60% of participants had an undetect-
able plasma HIV RNA 24 weeks after release and close to 
80% attended at least 1 community clinic appointment. By 
contrast, Baillargeon et al14 reported that just 18% of HIV-
infected men and women released from TX state prisons 
between 2004 and 2007 filled an ART prescription 30 days 
after release, increasing to only 30% by 60 days. Furthermore, 
in a subanalysis of 1750 of the releasees returning to the 
greater Houston area, 28% had a record of attending an HIV 
clinic by 90 days after release.44
However, unlike the imPACT trial, the study by 
Baillargeon et al included those without as well as with viral 
suppression at the time of release. Individuals unable to achieve 
control of their HIV infection in prison can be expected to face 
considerable challenges doing so in the less-structured environ-
ment of their community. While in their study less than half of 
the HIV-infected individuals released from the TX prison 
system during the period of study had achieved an undetectable 
viral load during incarceration, those that did had a significantly 
higher likelihood of filling their ART prescription during the 3-
month postrelease observation period. As ART fill rates were 
greater in this subgroup and increased over time after release, it 
is conceivable that a substantial proportion of those who left 
prison with an undetectable viral load filled their HIV 
medication prescription at 6 months after release.
It is also notable that the rates of viral suppression 
Springer et al15 reported in their study of prison releasees in 
New Haven with opioid dependency were comparable with 
those found in the imPACT trial, with 55% of the control arm 
having an undetectable HIV RNA level at week 24 after their 
release. In that study, 73% had a plasma HIV RNA level ,400 
copies/mL at baseline and, again, undetectable viremia at study 
entry was strongly associated with viral suppression at 24 weeks.
In the imPACT trial, those randomized to a comprehen-
sive intervention—designed to enhance motivation and self-
efficacy to access community HIV care, minimize barriers to 
such care, and support ART adherence—were no more likely 
to maintain viral suppression than those receiving standard 
prerelease discharge planning only. Specifically, analyses 
including multiple imputation of missing HIV-1 RNA levels 
found similar rates of viral suppression and failed to detect 
a significant difference in the primary outcome between the 
study arms. Participants in both study groups experienced 
a steady and similar loss of prerelease viral suppression after 
release. Likewise, viremia copy-years, which quantifies the 
cumulative HIV-1 RNA exposure over time, was similar 
between the study groups. Approximately a third of partic-
ipants in each study arm did not contribute data at the 24-
week postrelease time point, and in our primary ITT analysis, 
we used multiple imputation to impute missing values. Most 
of these participants were reincarcerated, and it is possible, if 
not likely, that many of those returning to prison re-
established suppression of HIV. In analyses that excluded 
those who were reincarcerated or lost to follow-up for another 
reason, no statistically significant difference in 24-week 
postrelease viral suppression was found.
Previous studies of HIV-infected releasees highlight the 
many challenges the formerly incarcerated face in success-
fully managing their HIV infection.45–47 Although most of the 
participants were able to maintain viral suppression over the 
course of postrelease follow-up, the steady decline in viral 
suppression observed in the imPACT arm, despite its 
multilevel and evidence-based components, may be due to 
a profound counter effect from forces that were not addressed 
adequately by the intervention. There may have been 
limitations to the support that clinical care centers could 
provide to these individuals—newly released from prison and 
saddled with comorbid substance use and mental health 
disorders, poverty, homelessness, lack of social support, and 
myriad other challenges. HIV-infected prisoners facing 
multiple critical life needs that make it difficult for consistent 
HIV care engagement to be a top priority is a well-described 
phenomenon.45,46 Our results also imply a need for inter-
ventions that directly address the chaotic social environments 
to which former inmates return and the pervasive and 
entrenched contextual factors, such as discrimination, 
inequality, poverty reinforcing policies, and practices—col-
lectively termed, structural violence48—that act as obstacles 
to desired outcomes such as long-lasting suppression of HIV.
Alternatively, study participation itself could have 
served as an intervention that promoted care engagement, 
ART access, and viral suppression—including in the control 
arm. Participants in both study arms received flip-type 
cellphones at release. In the case of the control participants, 
these phones were intended to facilitate study retention. It is 
unclear to what extent the phones were instrumental to health 
care access. In addition, regular contact with study data 
collection staff could have been perceived by participants as 
being supportive, and this too may have had a positive 
influence on the study outcomes.
In contrast to the absence of a difference in virologic 
outcomes when comparing the imPACT and standard-of-care 
arms, a significantly greater proportion of those in the 
intervention group accessed nonemergency community med-
ical care within 6 weeks of release than those in the standard-
of-care group (86% versus 75%; P = 0.02). The finding of 
a disconnect between access to community medical care and 
HIV-1 RNA levels suggests that linkage to care is insufficient 
when the objective is suppression of HIV viremia. A major 
assumption of the imPACT intervention was that linkage to 
community care, when combined with counseling to enhance 
motivation to engage in care, would lead to ART access and 
services that would support adherence and address unmet 
needs. This assumption is logical, as community clinics refill 
prescribed ART and early linkage to HIV care has been found 
to improve outcomes, including viral suppression. This model 
of linkage to community providers of care, rather than 
ongoing direct provision of such services, is also more 
sustainable. However, despite higher rates of community care 
engagement, those in the intervention arm fared no better 
virologically than those in the standard-of-care arm.
That engagement in HIV care does not ensure virologic 
success is also evident when considering the HIV Care 
Cascade, where the drop in the proportion of those having 
entered HIV care who are subsequently retained in care is the
ication adherence, and maintenance of viral suppression.
The characterization of these factors is essential to inform
policy and other strategic approaches to HIV prevention and
treatment in the United States.
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